Thinking big: How iPSC-derived therapies can get out of the niche
Tracks
Track 2
| Thursday, October 31, 2024 |
| 3:35 PM - 4:50 PM |
| Room 109 |
Details
This panel discussion will focus on the state of the art and current trends in the field of iPSC-derived cell therapies in terms of their potential, diversity, progress, and key challenges. Scientific, manufacturing, quality, regulatory, and economic parameters will be discussed in the context of other cell therapies and biologics. The panel will touch on emerging technologies such as modified / armoured cell therapies derived from iPSCs and on the range of new functionalities and features that these technologies confer.
The purpose of this session is to show that iPSCs are unfolding their potential in specific areas and that new technology can help iPSC-derived therapies become relevant in large disease indications.
Speaker
A/Prof. Ngaire Elwood
Director, BMDI Cord Blood Bank, Cord Blood Advanced Therapies Research Laboratory
Murdoch Children's Research Institute
Panellist
Prof Melissa Little
Chief Scientist, Group Leader-kidney Regeneration
Murdoch Children's Research Institute
Panellist
Dr. Bev Menner
CEO
Cell Therapies Pty Ltd
Panellist
